Related Experiment Video
Updated: May 7, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis
Shannon Cope1, James F Donohue, Jeroen P Jansen
1Division of Clinical Science, St George's University of London, London SW17 0RE, UK. pjones@sgul.ac.uk.
Respiratory Research
|October 8, 2013
Summary
Indacaterol, glycopyrronium, and tiotropium are the most effective bronchodilators for COPD. This study compared their efficacy against other treatments using a Bayesian network meta-analysis.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Choosing optimal bronchodilators for COPD is challenging due to new treatment options.
- This study evaluates several once-daily and twice-daily bronchodilators for moderate to severe COPD.
Purpose of the Study:
- To compare the efficacy of indacaterol, glycopyrronium bromide, tiotropium bromide, salmeterol, formoterol, and placebo in COPD patients.
- To assess key respiratory outcomes including lung function and quality of life.
Main Methods:
- A Bayesian network meta-analysis of 40 randomized controlled trials.
- Evaluated trough and post-dose forced expiratory volume in 1 second (FEV1), St. George's Respiratory Questionnaire (SGRQ) scores, and Transition Dyspnea Index (TDI) scores at 6 months.
Main Results:
- Indacaterol (150-300 μg) showed higher trough FEV1 compared to placebo (152-160 mL increase) and the greatest SGRQ score improvement (-3.6 to -3.9 points).
- Glycopyrronium and tiotropium (18 μg) demonstrated the next best efficacy for FEV1 and SGRQ scores, with minimal differences between them.
Conclusions:
- Indacaterol, glycopyrronium, and tiotropium are anticipated to be the most effective bronchodilators for COPD.
- These findings aid clinicians in selecting appropriate treatments for COPD patients.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation